Virulizin-2gamma, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts.

C. Liu, E. S. Ferdinandi, G. Ely, Shantaram S Joshi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Virulizin-2gamma, a novel biological response modifier extracted from bovine bile, has shown in clinical studies a significant antitumor activity against pancreatic cancer. We report here the results of preclinical evaluation of Virulizin-2gamma in treatment of human pancreatic cancer xenograft in nude mice. In this in vivo study, 14 daily bolus intraperitoneal administrations of Virulizin-2gamma (0.2 ml/mouse/day) significantly inhibited the growth of BxPC-3 human pancreatic tumor xenografts, with T/C value of 60%. Virulizin-2gamma also potentiated the antitumor activity of gemcitabine (120 mg/kg x4, q3d) in this tumor model. The combination therapy resulted in T/C values of 26% compared to gemcitabine alone (T/C 33%). In addition, based on body weight observation, no signs of toxicity related to treatment with Virulizin-2gamma, either as a single agent or when combined with gemcitabine were found. Virulizin-2gamma was well tolerated by the mice. The data from in vitro studies revealed that Virulizin-2gamma did not have direct cytotoxicity against cultured tumor cell lines, indicating that the in vivo antitumor activity is likely due to its immunomodulating effects on host immune cells. These preclinical results supported the safety and efficacy observed in clinical studies and indicated that Virulizin-2gamma is a promising immunotherapeutic agent for treatment of pancreatic cancer and worthy of further clinical evaluation.

Original languageEnglish (US)
Pages (from-to)1015-1020
Number of pages6
JournalInternational journal of oncology
Volume16
Issue number5
StatePublished - May 2000

Fingerprint

Pancreatic Neoplasms
Heterografts
gemcitabine
Cultured Tumor Cells
virulizin
Immunologic Factors
Tumor Cell Line
Nude Mice
Bile
Neoplasms
Body Weight
Observation
Safety
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Virulizin-2gamma, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts. / Liu, C.; Ferdinandi, E. S.; Ely, G.; Joshi, Shantaram S.

In: International journal of oncology, Vol. 16, No. 5, 05.2000, p. 1015-1020.

Research output: Contribution to journalArticle

@article{4c99c15700304d87bac9178b3443e4aa,
title = "Virulizin-2gamma, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts.",
abstract = "Virulizin-2gamma, a novel biological response modifier extracted from bovine bile, has shown in clinical studies a significant antitumor activity against pancreatic cancer. We report here the results of preclinical evaluation of Virulizin-2gamma in treatment of human pancreatic cancer xenograft in nude mice. In this in vivo study, 14 daily bolus intraperitoneal administrations of Virulizin-2gamma (0.2 ml/mouse/day) significantly inhibited the growth of BxPC-3 human pancreatic tumor xenografts, with T/C value of 60{\%}. Virulizin-2gamma also potentiated the antitumor activity of gemcitabine (120 mg/kg x4, q3d) in this tumor model. The combination therapy resulted in T/C values of 26{\%} compared to gemcitabine alone (T/C 33{\%}). In addition, based on body weight observation, no signs of toxicity related to treatment with Virulizin-2gamma, either as a single agent or when combined with gemcitabine were found. Virulizin-2gamma was well tolerated by the mice. The data from in vitro studies revealed that Virulizin-2gamma did not have direct cytotoxicity against cultured tumor cell lines, indicating that the in vivo antitumor activity is likely due to its immunomodulating effects on host immune cells. These preclinical results supported the safety and efficacy observed in clinical studies and indicated that Virulizin-2gamma is a promising immunotherapeutic agent for treatment of pancreatic cancer and worthy of further clinical evaluation.",
author = "C. Liu and Ferdinandi, {E. S.} and G. Ely and Joshi, {Shantaram S}",
year = "2000",
month = "5",
language = "English (US)",
volume = "16",
pages = "1015--1020",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Virulizin-2gamma, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts.

AU - Liu, C.

AU - Ferdinandi, E. S.

AU - Ely, G.

AU - Joshi, Shantaram S

PY - 2000/5

Y1 - 2000/5

N2 - Virulizin-2gamma, a novel biological response modifier extracted from bovine bile, has shown in clinical studies a significant antitumor activity against pancreatic cancer. We report here the results of preclinical evaluation of Virulizin-2gamma in treatment of human pancreatic cancer xenograft in nude mice. In this in vivo study, 14 daily bolus intraperitoneal administrations of Virulizin-2gamma (0.2 ml/mouse/day) significantly inhibited the growth of BxPC-3 human pancreatic tumor xenografts, with T/C value of 60%. Virulizin-2gamma also potentiated the antitumor activity of gemcitabine (120 mg/kg x4, q3d) in this tumor model. The combination therapy resulted in T/C values of 26% compared to gemcitabine alone (T/C 33%). In addition, based on body weight observation, no signs of toxicity related to treatment with Virulizin-2gamma, either as a single agent or when combined with gemcitabine were found. Virulizin-2gamma was well tolerated by the mice. The data from in vitro studies revealed that Virulizin-2gamma did not have direct cytotoxicity against cultured tumor cell lines, indicating that the in vivo antitumor activity is likely due to its immunomodulating effects on host immune cells. These preclinical results supported the safety and efficacy observed in clinical studies and indicated that Virulizin-2gamma is a promising immunotherapeutic agent for treatment of pancreatic cancer and worthy of further clinical evaluation.

AB - Virulizin-2gamma, a novel biological response modifier extracted from bovine bile, has shown in clinical studies a significant antitumor activity against pancreatic cancer. We report here the results of preclinical evaluation of Virulizin-2gamma in treatment of human pancreatic cancer xenograft in nude mice. In this in vivo study, 14 daily bolus intraperitoneal administrations of Virulizin-2gamma (0.2 ml/mouse/day) significantly inhibited the growth of BxPC-3 human pancreatic tumor xenografts, with T/C value of 60%. Virulizin-2gamma also potentiated the antitumor activity of gemcitabine (120 mg/kg x4, q3d) in this tumor model. The combination therapy resulted in T/C values of 26% compared to gemcitabine alone (T/C 33%). In addition, based on body weight observation, no signs of toxicity related to treatment with Virulizin-2gamma, either as a single agent or when combined with gemcitabine were found. Virulizin-2gamma was well tolerated by the mice. The data from in vitro studies revealed that Virulizin-2gamma did not have direct cytotoxicity against cultured tumor cell lines, indicating that the in vivo antitumor activity is likely due to its immunomodulating effects on host immune cells. These preclinical results supported the safety and efficacy observed in clinical studies and indicated that Virulizin-2gamma is a promising immunotherapeutic agent for treatment of pancreatic cancer and worthy of further clinical evaluation.

UR - http://www.scopus.com/inward/record.url?scp=0034186639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034186639&partnerID=8YFLogxK

M3 - Article

C2 - 10762639

AN - SCOPUS:0034186639

VL - 16

SP - 1015

EP - 1020

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -